Download Free Sample Report

Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.
This report contains market size and forecasts of Entrectinib in global, including the following market information:

• Global Entrectinib Market Revenue, 2018-2023, 2023-2030, ($ millions)
• Global Entrectinib Market Sales, 2018-2023, 2023-2030, (Kg)
• Global top five Entrectinib companies in 2022 (%)

The global Entrectinib market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
0.99 Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Entrectinib include BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Entrectinib manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Entrectinib Market, by Purity, 2018-2023, 2023-2030 ($ Millions) & (Kg)
Global Entrectinib Market Segment Percentages, by Purity, 2022 (%)

• 0.99
• 0.98

Global Entrectinib Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (Kg)
Global Entrectinib Market Segment Percentages, by Application, 2022 (%)

• Anaplastic Lymphoma
• C-ros Oncogene

Global Entrectinib Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (Kg)
Global Entrectinib Market Segment Percentages, By Region and Country, 2022 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Entrectinib revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Entrectinib revenues share in global market, 2022 (%)
• Key companies Entrectinib sales in global market, 2018-2023 (Estimated), (Kg)
• Key companies Entrectinib sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

• BOCSCI
• APExBIO Technology
• Cayman Chemical
• ChemScence
• Crysdot
• Medical Isotopes
• TargetMol Chemicals
• Toronto Research Chemicals
• Beijing Jingming Biotechnology
• Cool Pharm
• Shanghai Lollane Biological Technology
• Shanghai Macklin Biochemical
• Shanghai Muse Health Tech
• ATK Chemical
• Shanghai Send Pharmaceutical Technology
• Shanghai Yuanye Bio-Technology
• Wuhan Sun-Shine Bio-Technology